ALK and non-small cell lung carcinoma: A multicenter, single-arm, phase I/II study conducted in Japan showed the benefit of alectinib in ALK rearrangement–positive NSCLC in patients who had not had previous ALK inhibitor exposure (Seto et al., 2013).